NCT04627701招募中不适用
Evaluation of the Safety and Efficacy of the Omega System for the Treatment of Benign Prostatic Hyperplasia
ProArc Medical4 个研究点 分布在 2 个国家目标入组 26 人开始时间: 2023年7月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 26
- 试验地点
- 4
- 主要终点
- Improvement in urinary related symptoms as evidenced by IPSS score
研究概览
简要总结
The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses a static diathermy incision mechanism to make a circumferential incision in the tissue surrounding the prostatic urethra into which the Omega shaped permanent implant is placed. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male ≥50 years of age
- •Diagnosed with symptomatic benign prostatic hyperplasia (BPH).
- •International Prostate Symptom Score (IPSS) >
- •Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).
- •Participant understands and is willing to the informed consent form.
- •Prostate Volume between 30cc and 80cc.
- •Prostate length ≥3cm and ≤5cm
排除标准
- •Concomitant participation in another interventional study.
- •Unable to comply with the clinical protocol including all the follow-up requirements.
- •Vulnerable population such as inmates or developmentally delayed individuals.
- •Significant comorbidities which would affect study participation.
- •Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.
- •Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:
- •Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.
- •Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.
- •Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
- •Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).
- •Patient is taking steroids. [Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers]
- •Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
- •Compromised renal function due to obstructive uropathy.
- •Active Urinary Tract Infection (UTI).
- •Obstructive or protruding median lobe
- •American Society of Anaesthesiologists score (ASA) >
- •Known neurogenic bladder or neurological disorders that might affect bladder or function.
- •Recent myocardial infarction (less than three months).
- •Concomitant bladder stones.
- •Current gross hematuria.
- •Active or history of epididymitis within the past 3 months.
- •Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
- •Confirmed or suspected malignancy of bladder.
- •History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.
- •Other Urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
- •Bacterial prostatitis within the last 12 months.
- •Previous rectal surgery, other than hemorrhoidectomy.
- •Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).
- •Known allergy to nickel or titanium or stainless steel.
结局指标
主要结局
Improvement in urinary related symptoms as evidenced by IPSS score
时间窗: 3 months
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic HyperplasiaBenign ProstaticHyperplasia (BPH)NCT02639442ProArc Medical29
进行中（未招募）
不适用
Clinical Investigation of Omega Refractive Capsule, Model VICataractNCT04574115Omega Ophthalmics30
已完成
不适用
Clinical Investigation of Omega Refractive Capsule Model V With Use of an FDA Approved IOLCataractNCT04574102Omega Ophthalmics6
Unknown
不适用
Modified Reconstruction for Pancreatic Head ResectionFistula PancreaticoduodenalNCT03277625St. Josef Hospital Bochum200
已完成
2 期
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)End Stage Renal DiseaseNCT00110929Amgen850